Search

Search Constraints

You searched for: Issue Volume 32(2022)Supplement 2

Search Results

1. 2022-LBA-1183-ESGO Lymphedema appearance according to nodal staging in endometrial cancer. (27th October 2022)

2. 2022-LBA-1231-ESGO Use of mass cytometry analysis of human peripheral blood mononuclear cells to identify cell subsets for monitoring combined immunotherapy with CD73 and PD-L1 blockade in HGSOC patients. (27th October 2022)

3. 2022-LBA-1282-ESGO Identifying women with early-stage cervical cancer at low risk of lymph node metastases, in a large international cohort – A logistic regression analysis, without sharing privacy-sensitive patient data. (27th October 2022)

4. 2022-LBA-1382-ESGO Genomic signatures for the prediction of recurrence and metastasis in Endometrial Cancer. (27th October 2022)

6. 2022-LBA-1663-ESGO Should delayed debulking/cytoreductive surgery be offered to all advanced ovarian/fallopian tubal cancer patients that did not have surgery?. (27th October 2022)

9. 2022-LBA-325-ESGO Patients with newly diagnosed ovarian cancer treated with maintenance rucaparib: exploratory biomarker analysis from the phase 3 ATHENA-MONO study (GOG-3020/ENGOT-ov45; NCT03522246). (27th October 2022)

10. 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. (27th October 2022)